Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ertugliflozin/metformin - Merck/Pfizer

Next Previous
Drug Profile

Ertugliflozin/metformin - Merck/Pfizer

Alternative Names: MK 8835/metformin; MK 8835B; SEGLUROMET

Latest Information Update: 18 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; Pfizer
  • Class Antihyperglycaemics; Biguanides; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 16 Feb 2022 No development reported - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment) in Ukraine, South Korea, Israel, Russia, Philippines, Canada, Argentina, Georgia, Colombia, Hong Kong, Mexico, New Zealand, Serbia, South Africa, Thailand, Turkey (PO)
  • 27 Dec 2019 Merck & Co and Pfizer completes the VERTIS-CV phase III in Type-2 diabetes mellitus (Adjunctive treatment) in the US, the UK, Ukraine, Turkey, Thailand, South Africa, Slovakia, Serbia, Romania, Poland, New Zealand, Netherlands, Mexico, Lithuania, Latvia, Hungary, Hong Kong, Greece, Georgia, Czech Republic, Colombia, Bulgaria and Argentina (NCT01986881)
  • 01 Mar 2018 Registered for Type-2 diabetes mellitus in European Union, Norway, Iceland and Liechtenstein (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top